Citizens Keeps Exelixis Rating Following FDA Review Extension

Citizens reiterated its Market Outperform rating and $55.00 price target on Exelixis (NASDAQ: EXEL) after the FDA extended its review timeline for the cancer candidate zanzalintinib by three months. The delay moves the target action date from December 3, 2026, to March 3, 2027. Analysts view this as a procedural adjustment rather than a signal of clinical failure.

"In our view, these events are likely based on FDA procedure and are not indicative of a significant application issue," said Silvan Turkcan, an analyst at Citizens, in a note to investors.

Why the FDA Extended the Review

The extension occurred after Exelixis submitted updated safety and efficacy data in response to an agency information request. Under FDA regulatory guidelines, the submission of substantial new information during the review period is classified as a major amendment. This designation grants the agency additional time to evaluate the new data, which typically results in a three-month extension of the Prescription Drug User Fee Act (PDUFA) date.

William Blair analysts stated the risk of rejection remains low because the combination of zanzalintinib and Tecentriq showed an overall survival benefit in the Phase 3 STELLAR-303 study. The study demonstrated efficacy across the intent-to-treat population, a metric for regulatory approval in metastatic colorectal cancer.

Financial Context and Market Position

The potential approval of zanzalintinib is a component of the company's long-term growth strategy as its existing portfolio faces competitive pressures. The Exelixis cabozantinib franchise generated approximately $2.12 billion in revenue during fiscal year 2025. Analysts monitor this revenue stream as the company navigates potential patent cliff considerations.

For investors, the primary concern is the transition from the established cabozantinib business to the next generation of therapies. The $55.00 price target from Citizens is derived from a discounted cash flow (DCF) analysis, which accounts for the expected contribution of zanzalintinib to the company's earnings profile.